Tripelennamine HCl
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318957

CAS#: 154-69-8 (HCl)

Description: Tripelennamine, also known as Pyribenzamine, is a drug that is used as an antipruritic and first-generation antihistamine. It can be used in the treatment of asthma, hay fever, rhinitis and urticaria, but is now less common as it has been replaced by newer antihistamines. It is a member of the pyridine and ethylenediamine classes.

Chemical Structure

img
Tripelennamine HCl
CAS# 154-69-8 (HCl)
Instruction

Theoretical Analysis

MedKoo Cat#: 318957
Name: Tripelennamine HCl
CAS#: 154-69-8 (HCl)
Chemical Formula: C16H22ClN3
Exact Mass: 0.00
Molecular Weight: 291.823
Elemental Analysis: C, 65.85; H, 7.60; Cl, 12.15; N, 14.40

Price and Availability

Size Price Availability Quantity
1g USD 150 2 Weeks
5g USD 450 2 Weeks
25g USD 850 2 Weeks
Bulk inquiry

Related CAS #: 154-69-8 (HCl)   91-81-6 (free base)    

Synonym: Piristin; Pyrinamine; Stanzamine; Tripelennamine; Pyribenzamine.

IUPAC/Chemical Name: N,N-dimethyl-N-(phenylmethyl)-N-pyridin-2-ylethane-1,2-diamine hydrochloride

InChi Key: FSSICIQKZGUEAE-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H21N3.ClH/c1-18(2)12-13-19(16-10-6-7-11-17-16)14-15-8-4-3-5-9-15;/h3-11H,12-14H2,1-2H3;1H

SMILES Code: CN(C)CCN(CC1=CC=CC=C1)C2=NC=CC=C2.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info: Related CAS# CAS#154-69-8 ( Tripelennamine HCl); CAS#91-81-6 ( Tripelennamine free base)

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 291.82 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Fokken D Bspharm. Case report: tripelennamine in the treatment of skin disorders in horses. Int J Pharm Compd. 2009 Sep-Oct;13(5):388-9. PubMed PMID: 23966537.

2: Manohar M, Goetz TE, Humphrey S, Depuy T. H1-receptor antagonist, tripelennamine, does not affect arterial hypoxemia in exercising Thoroughbreds. J Appl Physiol (1985). 2002 Apr;92(4):1515-23. PubMed PMID: 11896018.

3: Wasfi IA, Boni NS, Elghazali M, Alkatheeri NA, Abdel Hadi AA, Al Muharami AM, Barezaig IM. Lack of effect of repeated administration of tripelennamine on antipyrine disposition in camels. J Vet Pharmacol Ther. 2000 Dec;23(6):409-12. PubMed PMID: 11168921.

4: Wasfi IA, Abdel Hadi AA, Elghazali M, Boni NS, Alkatheeri NA, Barezaig IM, Al Muharami AM, Hamid AM. Comparative disposition of tripelennamine in horses and camels after intravenous administration. J Vet Pharmacol Ther. 2000 Jun;23(3):145-52. PubMed PMID: 11110101.

5: Johanson CE, Evans S, Henningfield J. The discriminative stimulus effects of tripelennamine in humans. Psychopharmacology (Berl). 1996 Jul;126(2):140-6. PubMed PMID: 8856833.

6: Lima JL, Montenegro MC, Sales MG. Construction and evaluation of PVC conventional and tubular tripelennamine-selective electrodes: their application in pharmaceutical preparations. J Pharm Biomed Anal. 1996 Jun;14(8-10):931-8. PubMed PMID: 8817997.

7: Addington J, el-Guebaly N. Intravenous tripelennamine abuse in schizophrenia. Can J Psychiatry. 1996 Feb;41(1):63. PubMed PMID: 8919430.

8: McGwier BW, Alpert MA, Panayiotou H, Lambert CR. Acute myocardial infarction associated with intravenous injection of pentazocine and tripelennamine. Chest. 1992 Jun;101(6):1730-2. PubMed PMID: 1600804.

9: Yeh SY. Metabolic profile of tripelennamine in humans. J Pharm Sci. 1991 Sep;80(9):815-9. PubMed PMID: 1800700.

10: Suzuki T, Masukawa Y, Shiozaki Y, Misawa M. Potentiation of pentazocine conditioned place preference by tripelennamine in rats. Psychopharmacology (Berl). 1991;105(1):9-12. PubMed PMID: 1836064.

11: Yeh SY. N-depyridination and N-dedimethylaminoethylation of tripelennamine and pyrilamine in the rat. New metabolic pathways. Drug Metab Dispos. 1990 Jul-Aug;18(4):453-61. PubMed PMID: 1976067.

12: Hudzik TJ, Slifer BL. The role of dopamine in the effects of pentazocine and tripelennamine. Pharmacol Biochem Behav. 1990 Jul;36(3):547-54. PubMed PMID: 1974066.

13: Huston-Lyons D, Bain GT, Kornetsky C. Opiate dependence alters central reward of nalbuphine or pentazocine plus tripelennamine. Eur J Pharmacol. 1989 Oct 4;169(1):153-7. PubMed PMID: 2599009.

14: Vaupel DB. Tripelennamine interactions with the psychotomimetic sigma agonist N-allylnormetazocine. Pharmacol Biochem Behav. 1989 Jul;33(3):717-20. PubMed PMID: 2555824.

15: Vaupel DB. Interactions between pentazocine and tripelennamine on autonomic and nociceptive measures in the dog. Pharmacol Biochem Behav. 1989 May;33(1):245-51. PubMed PMID: 2780781.

16: Korfmacher WA, Freeman JP, Hansen EB Jr, Holder CL, Getek TA. Characterization of the antihistamines tripelennamine, methapyrilene, and thenyldiamine and their N-oxides by thermospray mass spectrometry. J Anal Toxicol. 1989 Mar-Apr;13(2):94-6. PubMed PMID: 2567368.

17: Stern KN, Chait LD, Johanson CE. Reinforcing and subjective effects of oral tripelennamine in normal human volunteers. Behav Pharmacol. 1989;1(2):161-167. PubMed PMID: 11175399.

18: Yeh SY, Hsu FL. Quantitative metabolic profile of tripelennamine and pyrilamine in the rat. Drug Metab Dispos. 1988 May-Jun;16(3):499-502. PubMed PMID: 2900747.

19: Cerniglia CE, Hansen EB Jr, Lambert KJ, Korfmacher WA, Miller DW. Fungal transformations of antihistamines: metabolism of methapyrilene, thenyldiamine and tripelennamine to N-oxide and N-demethylated derivatives. Xenobiotica. 1988 Mar;18(3):301-12. PubMed PMID: 2898181.

20: True WR, Poklis A, Jamieson RW, Seyfried W. Pentazocine-naloxone experimenters among abusers of pentazocine and tripelennamine from a VA treatment population. Int J Addict. 1988 Feb;23(2):217-26. PubMed PMID: 3366497.